Results shared at International Association for the Study of Pain (IASP) 2024 World Congress on Pain demonstrate that cebranopadol produces potent and prolonged pain relief with 25% less respiratory depression and significantly slower onset of effect with fewer respiratory adverse effects compared to oxycodone Findings highlight therapeutic potential of cebranopadol, an investigational treatment with a…
Category: Pain
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Prolonged release capsules for pain
Neuraxpharm launches Tapimio® (tapentadol) prolonged release capsules in the UK Neuraxpharm announced on June 30th 2022 the launch of Tapimio® (tapentadol) for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. Tapimio® is the first and only prolonged release capsule formulation of tapentadol to be made available…
Promising interim results for Ajovy
PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
